HBV-induced cirrhosis patients with SBP.
Conditions
Interventions
Four groups:NA
Sponsors
Beijing Ditan Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Compensated cirrhosis patients: 1) older than 18; 2) chronic HBV infection; 3) liver biopsy within 6 months: Ishak score=F5, or imaging (color Doppler ultrasound, CT or MRI) suggest cirrhosis (such as B ultrasound shows the liver shrinks with uneven surface, inhomogeneous echo or nodular enhancement, portal or spleen vein widening, or gastroscopy testifies esophageal-gastro varices, etc.) or Fibroscan value greater than 12kpa; 4) Child-Pugh 0.5 ng / ml, excluding infection in other parts; 4. Healthy control group: (1) Compliance with WHO's definition of health (ie, physical fitness, good spirit and social well-being); (2) No abnormality in liver function tests.
Exclusion criteria
Exclusion criteria: 1. Compensated cirrhosis patients: (1) decompensated cirrhosis; (2) hepatocellular carcinoma; (3) ever used or currently using antibiotics, prebiotics, probiotics or protons Pump inhibitors; (4) acute and chronic hepatitis with non-HBV virus, HCV infection, HDV infection, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosis cholangitis, Genetic metabolic liver diseases, drugs or toxic hepatitis alcoholic liver disease; (5) serious underlying diseases including chronic respiratory failure, circulatory failure, renal failure, etc. or organ transplantation, immunodeficiency; (6) pregnancy or lactating women and those who plan be pregnant during the study period; (7) Those participating in other clinical trials; (8) Others that the researcher considers unsuitable for enrollment. 2. Cirrhosis patients with ascites: (1) ever had or have hepatic encephalopathy; (2) ever had or have upper gastrointestinal bleeding; (3) hepatocellular carcinoma; (4) ever used or currently using antibiotics, prebiotics, probiotics or protons Pump inhibitors; (5) acute and chronic hepatitis with non-HBV virus, HCV infection, HDV infection, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosis cholangitis, Genetic metabolic liver diseases, drugs or toxic hepatitis alcoholic liver disease; (6) serious underlying diseases including chronic respiratory failure, circulatory failure, renal failure, etc. or organ transplantation, immunodeficiency; (7) pregnancy or lactating women and those who plan be pregnant during the study period; (8) Those participating in other clinical trials; (9) Others that the researcher considers unsuitable for enrollment. 3. Cirrhosis patients with SBP: meeting the exclusion criteria for cirrhosis patients with ascites. 4. healthy control group: (1) HBV infection or other diseases; (2) antibiotics, prebiotics, probiotics or traditional Chinese medicine were used or in use in the last 1 week.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cirrhosis dysbiosis ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| MELD score; | — |
Countries
China
Contacts
Public ContactHuichun Xing
Beijing Ditan Hospital Capital Medical University
Outcome results
None listed